The Pioneers in the Development of Personalized Immunotherapy: Dendreon

Cancer Immunotherapy is considered to be an artificial stimulation of the immune system. The core purpose of this entity is to treat cancer. It is done by improving the system’s natural ability to fight cancer. That is exactly what Dendreon does.

Dendreon was founded on the belief that immunotherapy made from a patient’s own cells will transform cancer treatment; Dendreon is fighting for patients by making the battle against cancer personal. The first R&D facility to be activated was on 1993 and soon Antigen Delivery Cassette was developed, which became the basis of the Active Cellular Immunotherapy platform. By harnessing the power of the body’s immune system, the company helped extend the lives of patients battling cancer. Truly it is considered to be a noble cause since many suffer from this problem and have undergone a lot of pain.

Its flagship product, PROVENGE^® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since its approval in 2010, nearly 30,000 men with advanced prostate cancer have been prescribed PROVENGE. Today, it continues to push its research forward so that it may help even more patients fight cancer with personalized immunotherapy.

In the fight against cancer, all its patients aren’t giving up, and neither is Dendreon. It aims to extend life without reducing the quality of life. This commitment — to patients, families, and the physicians who treat them — drives all that it does.

By the year 2013 more than 10,000 men prescribed for PROVENGE and soon hit the 20,000 mark by 2015. The same year Valeant Pharmaceuticals acquires Dendreon for $495 million. But soon after a year, Dendreon resumes operations as a standalone company following the acquisition by Sanpower Group for $819.9 million. Now over 30,000 men prescribed PROVENGE.

Factors that Makes PROVENGE Special

PROVENGE reprograms the body’s own immune cells to detect and attack cancer cells, with little impact on healthy tissue or cells. Additionally, PROVENGE may enable the immune system to fight prostate cancer cells as they change. This is because cancer cells that have been destroyed release identifying information into the bloodstream, which the immune system is trained to recognize and attack, should prostate cancer cells reappear. In both clinical and real-world settings, PROVENGE has been proven to increase overall survival. PROVENGE has been available in the United States since 2010. It is the first and only FDA-approved immunotherapy for the treatment of advanced prostate cancer made from a patient’s own immune cells. That gives us enough reasons to believe why this groundbreaking treatment has been prescribed by more than 30,000 men with advanced prostate cancer, helping many live longer.

The Company Functions

The company is completely dedicated to its Patients. All the members of the company make sure the fight against cancer is smooth and easy. It creates immunotherapy from a patient’s own immune cells by providing immunotherapy treatments that are clinically proven to help extend life, with a generally well-tolerated safety profile Also offers services and support that improve treatment access.

The company is supporting Clinical Practices by partnering with physicians, nurses, and clinicians as they continue to realize the full potential of immunotherapy. Further, helps urologists identify patients who will get the most out of immunotherapy.

The firm is always focused on the future by expanding access to PROVENGE for more patients, in the United States, and around the world. It is also investigating the earlier-stage treatment of prostate cancer with PROVENGE, with the goal of helping even more patients. Hence, is now exploring the use of personalized immunotherapy to treat other cancer types

Recent Press Releases

Recently Dendreon Initiated a Large-Scale Clinical Trial to Investigate PROVENGE^® (sipuleucel-T) in Men with Early-Stage Prostate Cancer on Active Surveillance. This took place in May of this year and the operation has shown some new and amazing news. All in all, the firm is working day and out to see this problem.

During the month of June Dendreon Publishes New Data in Clinical Cancer Research Correlating the Magnitude of Cytotoxic T Cell Response to PROVENGE^® (sipuleucel-T) Treatment with Overall Survival. This shows the company is doing its best to reach out to each and every patient.

The Chieftain

Jim Caggiano, CEO: A seasoned and dynamic leader with a proven track record of creating significant value in turnaround situations, Mr. Caggiano has nearly 30 years of experience in the biotechnology, pharmaceutical, and medical device marketplaces.

Under Mr. Caggiano’s leadership, Dendreon has been transformed into an exciting and growing enterprise that is making the fight against cancer personal by harnessing the power of the body’s immune system to fight back.

"Empowering the immune system to detect and attack cancer cells"